Market Alert: Trump Revives Trade War Playbook with Tariff Threats
Aumake Limited (ASX: AUK) has announced a refreshed business and board structure to support its FY26 strategic goals. The Company will focus on six core objectives, aiming to enhance profitability and adapt its business model to market dynamics. These include pursuing EBITA-accretive brand acquisitions in the health supplements and functional foods segment, transitioning China-facing retail units to lower-cost models, and aggressively simplifying and reducing costs across subsidiaries. Additionally, Aumake plans to pilot hospital channel distribution in China through exclusive partnerships, activate cross-border sales in China and the U.S. via the ZoomCoo alliance, and explore international distribution of China-sourced products.
To support these goals, Aumake will operate under two core business units: AUMAKE GLOBAL, covering joint ventures with ZoomCoo and 168 Express under the leadership of Joshua Zhou, and AUMAKE CHINA, covering its Hong Kong and mainland Chinese entities, led by Hai Yun Chen. This reorganisation aims to improve cash flow, profitability, and execution across growth initiatives.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Jul 17, 2025
Jul 17, 2025
Jul 17, 2025
Jul 17, 2025
Jul 17, 2025
Jul 17, 2025
Jul 17, 2025
Jul 17, 2025
Jul 17, 2025
Jul 17, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
